SCHEMBL1710495

SCHEMBL1710495

CNCCC(O)c1cccc(S(=O)(=O)CC2CCCCC2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HTR2A P28223 1/20 0.35
HRH1 P35367 1/20 0.35
OPRD1 P41143 1/20 0.35
OPRK1 P41145 1/20 0.35
SLC6A2 P23975 1/20 0.35
ADRB3 P13945 3/20 0.35
AGTR2 P50052 1/20 0.35
HSD17B10 Q99714 1/20 0.34
BCHE P06276 1/20 0.34
RAB9A P51151 2/20 0.34
ADRB2 P07550 1/20 0.34
ADRB1 P08588 1/20 0.34
HTR1A P08908 1/20 0.34
ADRA2A P08913 1/20 0.34
TSHR P16473 1/20 0.34
ADRA2B P18089 1/20 0.34
ADRA2C P18825 1/20 0.34
NFKB1 P19838 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1710530 0.87 AGTR2 (0.37) ALDH1A1SMN1; SMN2AGTR2
SCHEMBL1710688 0.86 AGTR2 (0.37) ALDH1A1SMN1; SMN2AGTR2
SCHEMBL13400238 0.83 HDAC6 (0.38) ALDH1A1SMN1; SMN2OPRD1OPRK1
SCHEMBL13400241 0.83 CA1 (0.40) ALDH1A1SMN1; SMN2OPRD1OPRK1
SCHEMBL13400165 0.83 AGTR2 (0.35) ALDH1A1SMN1; SMN2AGTR2BCHE
SCHEMBL1710554 0.80 AGTR2 (0.38) ALDH1A1SMN1; SMN2AGTR2BCHERAB9A
SCHEMBL1710497 0.80 ALDH1A1 (0.38) ALDH1A1SMN1; SMN2OPRD1OPRK1AGTR2
SCHEMBL13400220 0.79 ALDH1A1 (0.35) ALDH1A1SMN1; SMN2AGTR2HSD17B10RAB9A
SCHEMBL1710552 0.78 POLB (0.36) ALDH1A1SMN1; SMN2AGTR2BCHERAB9A
SCHEMBL3386705 0.78 ALDH1A1 (0.34) ALDH1A1SMN1; SMN2AGTR2BCHERAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2344451-A2 SULFUR-LINKED COMPOUNDS FOR TREATING OPTHALMIC DISEASES AND DISORDERS Acucela, Inc. (US) 2011-07-20 EP disclosed
US-20100093865-A1 SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS ACUCELA, INC. (US) 2010-04-15 US disclosed
US-20100093865-A1 SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS ACUCELA, INC. (US) 2010-04-15 US disclosed
US-20100093865-A1 SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS ACUCELA, INC. (US) 2010-04-15 US disclosed
WO-2010028088-A2 SULFUR-LINKED COMPOUNDS FOR TREATING OPTHALMIC DISEASES AND DISORDERS ACUCELA, INC. (US) 2010-03-11 WO disclosed
WO-2010028088-A2 SULFUR-LINKED COMPOUNDS FOR TREATING OPTHALMIC DISEASES AND DISORDERS ACUCELA, INC. (US) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093865-A1 SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS ALDH1A2, MPST, CLN6 ALDH1A1 314/4885SMN1; SMN2 129/4885HTR2A 3672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.